| name | es-lhfshd-treatment-approach |
| description | This skill identifies the appropriate treatment approach for luteinizing hormone/follicle-stimulating hormone deficiency (LH/FSHD) in childhood cancer survivors. It is triggered by clinician questions such as "How should I treat LH/FSHD in this survivor?" or "What sex hormone replacement is suitable for gonadotropin deficiency?" and recommends following the same hormone replacement strategies as in the noncancer population. |
Select LH/FSHD Treatment Regimen
STEP 1 — Gather Information
Collect radiation history (HP axis dose ≥30 Gy), tumor/surgery involving HP region, other pituitary deficits, pubertal status, serum LH, FSH, testosterone (males) or estradiol (females), bone health markers, and current medications (especially enzyme‑inducing antiepileptics).
Action: Proceed to assess LH/FSHD status.
STEP 2 — Rule In / Rule Out
Confirm LH/FSHD if gonadotropins are low or inappropriately normal with concomitant low sex hormones and clinical signs of delayed/absent puberty (no breast development by age 13 in girls, no testicular enlargement by age 14 in boys) or adult symptoms of hypogonadism.
Decision: If LH/FSHD is confirmed, move to classification; otherwise, consider alternative diagnoses and stop.
STEP 3 — Classify or Stratify
Stratify by sex and developmental stage: males → testosterone replacement; females → estrogen/progestin replacement; adjust regimen based on age (pediatric vs adult dosing) and assess baseline bone density.
Decision: Select the appropriate sex hormone replacement regimen per noncancer hypogonadism guidelines.
STEP 4 — Decide
Initiate testosterone (e.g., enanthate 50 mg IM monthly) in males or estradiol (e.g., transdermal patch) with cyclic progestin in females, titrate to age‑appropriate sex hormone levels, monitor lipids, hematocrit (testosterone) or thrombotic risk (estrogen), and repeat bone density annually.
Action: Treat and follow up per endocrine society hypogonadism guidelines.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on gonadotropin levels alone; low sex hormones must be confirmed. Avoid estrogen in patients with active thrombotic disease or uncontrolled hypertension. Watch for erythrocytosis and sleep apnea with testosterone therapy. Enzyme‑inducing antiepileptics (carbamazepine, phenytoin) may reduce hormone efficacy — consider dose adjustments or alternative agents. Ensure calcium/vitamin D supplementation and bone health surveillance. Do not delay treatment in symptomatic patients; GnRH analogs are not indicated for isolated LH/FSHD unless precocious puberty is present.
Concrete Clinical Example
A 16‑year‑old male survivor of medulloblastoma received 35 Gy craniospinal radiation, presents with absent pubertal development, low testosterone, and LH/FSH in the low‑normal range. After confirming LH/FSHD, testosterone enanthate 50 mg IM monthly is started, titrated to adult male ranges, with quarterly hematocrit and lipid checks and annual bone density assessment.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175
